








Nanofitins	 are	 cysteine-free	 protein	 scaffolds	 derived	 from	 the	 hyperstable	
DNA-binding	protein	Sac7d	(7	kDa,	66	amino	acids)	of	Sulfolobus	acidocaldarius	
[1].	 High-affinity	 nanofitins	 have	 been	 easily	 engineered	 by	 ribosome-display	
over	a	wide	range	of	targets	by	the	full	 randomization	of	10	to	14	amino	acid	
residues	localized	in	the	DNA-binding	site	of	Sac7d.	In	this	study,	the	anti-EGFR	
Nanofitin	 Cys−B10	 was	 site-specifically	 labeled	 with	 18F	 by	 site-specific	
















The	 radioactive	 18F−FBEM	 (molar	 activity:	 830	 MBq/nmol)	 was	 automatically	
synthetized	 on	 a	 FastLab	Multitracer	 (GE	 Healthcare)	 as	 previously	 described	
[2].	The	Nanofitin	Cys−B10	was	incubated	with	Ni−nitrilotriacetic	acid	magnetic	
beads	(GE	Healthcare)	in	the	presence	of	TCEP−HCl	(50	equiv,	30	min,	25	°C,	pH	
adjusted	 at	 8).	 Beads	were	washed	with	 phosphate	 buffer	 (200	mM,	 pH	 7.4)	
and	 incubated	with	18F−FBEM	freshly	resuspended	 in	phosphate	buffer.	Beads	


















In	 this	study,	we	provided	the	 first	 report	of	 the	use	of	 the	Nanofitin	
scaffold	 for	generating	targeted	PET	radiotracers,	using	the	anti-EGFR	
B10	Nanofitin	as	proof-of-concept.	18F−FBEM−Cys−B10	shows	a	favor-	
able	 in	 vivo	 profile.	 The	 possibility	 to	 drive	 Nanofitins	 molecular	
recognition	capability,	over	a	fast	and	tunable	in	vitro	selection	system,	







Targeting of the EGFR-positive tumor A431 by the radiolabeled anti-EGFR 
Nanofitin 
A Co-registered transversal sections of PET and CT 1 h after the injection of 18F−FDG (9 MBq) in a 
xenograft model under isoflurane anesthesia (blood glucose level of 73 mg/dL and weight of 29 g). He: 
heart. B Co-registered transversal sections of PET and MRI 2 h after injection in xenograft model under 






























Time-lapse	 microscopy	 on	 A431	 cells	 incubated	 with	 either	 Alexa	 Fluor	 488	









histological analysis of biopsies or surgically resected ti sues.
These antiquated methods fail to provide information about
heterogeneity of expression or changes in expression that occur
over time.6
A straightforward strategy for generating targeted PET
radiotracers has relied on the radiolabeling of therapeutic
monoclonal antibodies.7 Examples described in the literature
include 89Zr−trastuzumab,8 89Zr−tevacizumab,9 89Zr−tanitunu-
mab,10 and 89Zr−cetuximab as well as 64Cu−cetuximab.11,12
Immuno-PET radiotracers have shown some promises, but
their sensitivity remains limited due to their full IgG format
(∼150 kDa) and related biophysical characteristics (extended
residence in the bloodstream, slow tumor penetration, and slow
blood clearance).13−15 This r sults in high tumor accumulation,
yields to low tissue contrast,15 and requires late imaging time
points (at least 2 days after administration).16 Interestingly,
ScFv antibody fragments (∼25 kDa) show faster clearance but
only a moderate tumor accumulation.14 Studies focused on
analyzing the relation hip between the size of molecules and
their tumor uptake13,17 and show a U-shaped relationship
between these two parameters with a minimal accumulation of
molecules of the size of a ScFv. Smaller molecules, such as
nonimmunoglobulin alternative scaﬀolds (4 to 20 kDa), might
provide the optimal balance between a rapid clearance from
blood and nontarget tissue, vascular extravasation, and tissue
penetration while being amenable to a suﬃciently high aﬃnity
to provide tu or targeting for imaging applications.18 The
growing number of imaging ligands recently developed,
including aﬃbodies,19−21 ﬁbronectins,22,23 and darpins,24,25
have illustrated the suitability of non-IgG scaﬀolds for in vivo
tumor visualization. With their very short biological half-life (in
mi utes),18 alternative scaﬀolds ar perfectly well-suited for fast
imaging protocols in combination with rapid decaying radio-
isotopes, such as 68Ga (68 min) and 18F (110 min).
Additionally, fast imaging protocols with short physical half-
life radioisotopes facilitate handling of radioactive waste that
can be contained within the hospital facility with the current
common protocols already in place for 18F−ﬂuorodeoxyglucose
(18F−FDG).
Nanoﬁtins are cysteine-free protein scaﬀolds derived from
the hyperstable DNA-binding protein Sac7d (7 kDa, 66 amino
acids) of Sulfolobus acidocaldarius.26 High-aﬃnity nanoﬁtins
have been easily engineered by ribosome-display over a wide
range of targets (cell surface proteins,26 enzymes,27,28 GFP,29
IgG,30 cytokines,31 etc.) by the full randomization of 10 to 14
amino acid residues localized in the DNA-binding site of Sac7d
(Figure 1). This process allows the full redirecti n of the initial
DNA speciﬁcity of Nanoﬁtins to the binding of a target of
interest.26−32 Nanoﬁtins have kept their extreme stability from
Sac7d origin and have been proven robust enough to remain
active after one cycle of steam sterilization.29 Taking advantage
of their robustness and small size, Nanoﬁtins are currently
developed for challenging nonsystemic administration; orally
deliverable anti-TNF α Nanoﬁtins have entered a preclinical
development program in inﬂammatory bowel disease.31 Here,
we introduce the use of radiolabeled Nanoﬁtins as a new class
of molecular imaging probes with a suitable pharmacokinetic
proﬁle for the noninvasive diagnosis and monitoring of high
epidermal growth factor expressing solid tumors. The
epidermal growth factor receptor 1 (EGFR) is a trans-
membrane tyrosine-kinase receptor frequently found as over-
expressed or mutated in a variety of human tumors.33,34 In this
study, the anti-EGFR Nanoﬁtin Cys−B10 was site-speciﬁcally
labeled with 18F by site-speciﬁc conjugation with the prosthetic
group 18F−4-ﬂuorobenzamido−N-ethylamino-maleimide (18F−
FBEM), using a unique cysteine residue speciﬁcally introduced
in C-terminus (Figure 1). The resulting probe, 18F−FBEM−
Cys−B10, was then injected in a double-bearing tumor model
to evaluate the biodistribution and the ability of the
radiolabeled protein to speciﬁcally target in vivo the over-
EGFR-expressing A431 tumor.
■ RESULTS
Anti-EGFR B10 Nanoﬁtin. Anti-EGFR Nanoﬁtins were
identiﬁed upon several rounds of ribosome display29 using the
recombinant extracellular domain of human EGFR fused to a
Fc fragment (Creative Biomart) as a bait. Fusion of anti-EGFR
Nanoﬁtins to Pe38-KDEL toxins allowed the evaluation of their
internalization potential by monitoring IC50 of the constructs
on A431 cells, in comparison to a negative control involving the
anti-egg white lysozyme H4 Nanoﬁtin27,28,35−37 and referred
hereafter as IrrNF (Figure 2).
Pe38-KDEL toxin is a derivative of pseudomonas exotoxin A
that is lacking the cell entry domain required for its intracellular
mechanism of action. Only Nanoﬁtins triggering the internal-
ization of the toxin, i.e., with the Nanoﬁtin moiety replacing the
toxin cell entry domain, allow the restoration of the
internalization of the chimeric construct and its subsequent
cytotoxic activity. As with the negative control, no eﬀect on the
cell viability could be measured over concentrations of the
B10−PE38-KDEL construct ranging from 10−8 to 10−13 M.
This non-internalizing proﬁle appeared not to be shared with
Figure 1. Scheme of 18F−FBEM−Cys−B10 radiosynthesis. Positions randomized in the Nanoﬁtin libraries are labeled in red.
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accumulation in the bladder, only visible at the later time points
(Figure 6C). Taken together, these data suggest a renal
excretion of 18F−FBEM−Cys−B10, which is consistent for a
radioconjugate having a molecular weight below the cutoﬀ for
glomerular ﬁltration. Moreover, based on imaging and
biodistribution studies, the 18F−FBEM−Cys−B10 exhibits
low accumulations in blood (0.99 ± 0.20 %ID/g) and most
normal organs such as the heart (0.48 ± 0.14% ID/g), lung
(0.84 ± 0.59% ID/g), and spleen (0.77 ± 0.22% ID/g).
Biodistribution Study in BALB/c Nude Xenograft
Model. For the in vivo biology assessment, we developed a
double-bearing-tumor animal model using two human
carcinoma cell lines with opposite EGFR expression levels.
We injected in the right ﬂank of nude mice the over-expressing
Figure 7. Immunohistochemistry of A431 and H520 tumors grown on xenograft model. EGFR expression level was evaluated by staining tumors
slices with a rabbit anti-human EGFR antibody and a secondary goat ant-irabbit antibody conjugated to Alexa Fluor 488. Nuclei were counter stained
with 4',6-diamidino-2-phenylindole (DAPI; ×10).
Figure 8. Targeting of the EGFR-positive tumor A431 by the radiolabeled anti-EGFR Nanoﬁtin (A) Co-registered transversal sectio s of PET and
CT 1 h after the injection f 18F−FDG (9 MBq) in a xenograft model under isoﬂurane anesthesia (blood glucose level of 73 mg/dL and weight of 29
g). He: heart. (B) Co-registered transversal sections of PET nd MRI 2 h after injection in xenograft model und r isoﬂurane anesthesia of 18F−
FBEM−Cys−B10 (19 MBq/100 μL).
Table 1. Biodistribution of 18F−FBEM−Cys−B10 at 2.5 h Post-Injection
biodistribution in xenograft modela tumor-to-nontarget tissue count density ratiosb
tissues xenograft model uptake ratio xenograft model BALB/c
blood 0.32 ± 0.07 liver-to-blood 3.90 ± 1.33 4.80 ± 1.11
brain 0.02 ± 0.01 kidney-to-blood 4.82 ± 0.84 6.74 ± 2.43
bone 0.20 ± 0.01 A431-to-kidney 0.98 ± 0.29
liver 1.13 ± 0.52 A431-to-liver 1.43 ± 0.52
kidney 1.55 ± 0.57 A431-to-H520 2.53 ± 0.18
heart 0.17 ± 0.03 A431-to-lung 2.53 ± 0.89
spleen 0.27 ± 0.08 A431-to-blood 4.55 ± 0.63
skin 0.28 ± 0.12 A431-to-heart 8.56 ± 1.34
muscle 0.12 ± 0.03
lung 0.63 ± 0.31
tumor A431 1.42 ± 0.18
tumor H520 0.56 ± 0.10
aData are expressed in percentage of injected dose per gram of organ [%ID/g] ± SD after intravenous injection of the probe. bTumor-to-nontarget
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the two other anti-EGFR Nanoﬁtins NF1 and NF2. Toxicity of
the latter two Nanoﬁtin−Pe38-KDEL constructs is observed to
a diﬀerent extent with an half maximal inhibitory concentration
(IC50) value of 1.16 × 10−9 and 1.94 × 10−11 M, respectively,
which we attributed to a diﬀerent ability to trigger internal-
ization. Beside its noninternalizing behavior, the speciﬁcity and
eﬃciency of B10 at localizing at the membrane of EGFR over-
expressing A431 cell lines was evaluated by cell imaging and
ﬂow cytometry (Figure 3).
Time-lapse microscopy on A431 cells incubated with either
Alexa Fluor 488 labeled anti-EGFR B10 (1 μM) or anti-egg
white lysozyme H4 Nanoﬁtin (2 μM, negative control) revealed
a fast accumulation (visible after few seconds) of ﬂuorescence
on cells membrane for B10, while no targeting was observed
with the irrelevant Nanoﬁtin (Figure 3). The eﬀective
localization of B10 at the membrane of the cells was further
conﬁrmed by ﬂuorescence recovery after photobleaching A431
cell membranes (Figure S2), which resulted in instantaneous
recovery of ﬂuorescence, accounting for localization of the
labeling on the membrane. The analysis of the speciﬁcity of B10
Nanoﬁtin was complemented by a set of ﬂow-cytometry
experiments using A431 and H520 cells as EGFR-positive and
EGFR-negative cell lines, respectively. While no labeling could
Figure 2. Measurement of A431 cells viability after incubation with
Nanoﬁtins fused to the Pe38 toxin. A431 cells were incubated in the
presence of a concentration range of Nanoﬁtins−Pe38 fusion (10−8 to
10−13 M), and viability was measured after 7 days using a 2,3-bis (2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetra-
zolium hydroxide (XTT) assay. Data points represent the mean and
standard deviation of triplicate results. αEGFR_B10_Pe38-KDEL,
anti-EGFR B10 Nanoﬁtin; αEGFR_NF1- and NF2−Pe38-KDEL,
other anti-EGFR Nanoﬁtins; IrrNF−Pe38_KDEL, irrelevant Nano-
ﬁtin.
Figure 3. (A) In vitro speciﬁcity experiments of the Nanoﬁtin B10 cell surface labeling of A431 cells. Labeling of the A431 cells with a 2 μM solution
of an irrelevant Nanoﬁtin conjugated to Alexa Fluor 488 and a 1 μM solution of the anti-EGFR Nanoﬁtin B10 conjugated to Alexa Fluor 488. Images
were captured by time-lapse microscopy (7 images per second, 20× magniﬁcation) for 18 s, and the images given were obtained after 6 s of exposure.
( ) Binding and speciﬁcity analysis of the Nanoﬁtins B10−FIT and IrrNF−FITC (10 μM) binding to H520 (bottom) or A431 cells (top) and
cross-blocking experiment on A431 cells with B10−FITC pre-incubated with Cetuximab (1.1 μM). The EGFR binding of B10−FITC is represented
by a solid line, IrrNF−FITC is represented by a dotted line, and control cells without staining are represented by gray-shaded proﬁles. For the mean
ﬂuorescent intensity, please see Figure S1.
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Nanofitins.	
IrrNF−Pe38_KDEL,	irrelevant	Nanofitin.	
the two other anti-EGFR Nanoﬁtins NF1 and NF2. Toxicity of
the latter two Nanoﬁtin−Pe38-KDEL constructs is observed to
a diﬀerent extent with an half maximal inhibitory concentration
(IC50) value of 1.16 × 10−9 and 1.94 × 10−11 M, respectively,
which we attributed to a diﬀerent ability to trigger internal-
ization. Beside its noninternalizing behavior, the speciﬁcity and
eﬃciency of B10 at localizing at the membrane of EGFR over-
expressing A431 cell lines was evaluated by cell imaging and
ﬂow cytometry (Figure 3).
Time-lapse microscopy on A431 cells incubated with either
Alexa Fluor 488 labeled anti-EGFR B10 (1 μM) or anti-egg
white lysozyme H4 Nanoﬁtin (2 μM, negative control) revealed
a fast accumulation (visible after few seconds) of ﬂuorescence
on cells membrane for B10, while no targeting was observed
with the irrelevant Nanoﬁtin (Figure 3). The eﬀective
localization of B10 at the membrane of the cells was further
conﬁrmed by ﬂuorescence recovery after photobleaching A431
cell membranes ( igure S2), which resulted in instantaneous
recovery of ﬂuoresce ce, accounting for localization of the
labeling on the membrane. The ana ysis of the speciﬁcity of B10
Nanoﬁtin was complemented by a set of ﬂow-cytometry
experiments using A431 and H520 cells as EGFR-positive and
EGFR-negative cell lines, respectively. While no labeling could
Figure 2. Measurement of A431 cells viability after incubation with
Nanoﬁtins fused to the Pe38 toxin. A431 cells were incubated in the
presence of a concentration range of Nanoﬁtins−Pe38 fusion (10−8 to
10−13 M), and viability was measured after 7 days using a 2,3-bis (2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetra-
zolium hydroxide (XTT) assay. Data points represent the mean and
standard deviation of triplicate results. αEGFR_B10_Pe38-KDEL,
anti-EGFR B10 Nanoﬁtin; αEGFR_NF1- and NF2−Pe38-KDEL,
other anti-EGFR Nanoﬁtins; IrrNF−Pe38_KDEL, irrelevant Nano-
ﬁtin.
Figure 3. (A) In vitro speciﬁcity experiments of the Nanoﬁtin B10 cell surface labeling of A431 cells. Labeling of the A431 cells with a 2 μM solution
of an irrelevant Nanoﬁtin conjugated to Alexa Fluor 488 and a 1 μM solution of the anti-EGFR Nanoﬁtin B10 conjugated to Alexa Fluor 488. Images
were captured by t me-laps microscopy (7 images per seco d, 20× magniﬁcation) for 18 s, and the images given were obtained after 6 s of exposure.
(B) Binding and speciﬁcity analysis f the Nanoﬁtins B10−FITC and IrrNF−FITC (10 μM) binding to H520 (bottom) or A431 cells (top) and
cross-blocking experiment on A431 cells with B10−FITC pre-incubated with Cetuximab (1.1 μM). The EGFR binding of B10−FITC is represented
by a solid line, IrrNF−FITC is represented by a dotted line, and control cells without staining are represented by gray-shaded proﬁles. For the mean
ﬂuorescent inte sity, please see Figure S1.
Bioconjugate Chemistry Article
DOI:10.1021/acs.bioconjchem.7b00374
Bioconjugate Chem. XXXX, XXX, XXX−XXX
C
In	 vitro	 specificity	 experiments	 of	 the	
Nanofitin	 B10	 cell	 surface	 labeling	 of	 A431	
cells.	Labeling	of	the	A431	cells	with	a	2	μM	
solution	 of	 an	 irrelevant	 Nanofit in	
conjugated	 to	 Alexa	 Fluor	 488	 and	 a	 1	 μM	
solution	 of	 the	 anti-EGFR	 Na ofitin	 B10	
conjugated	to	Alexa	Fluor	488.	
A431	 tumor	 targeting	and	 specificity	of	 18F-labeled	B10	Nanofitin.	
Uptake	 in	 tumors	 of	 18F−FBEM−Cys−B10	 (2.1−9.1	 MBq)	 in	 mice	
carrying	EGFR-expressing	A431	tumors	without	blocking	(n	=	6)	or	
with	 blocking	 amounts	 of	 nonlabeled	 B10	 (500	 μg,	 n	 =	 6)	 or	
Cetuximab	(45	μg,	n	=	4)	injected	48	h	post-injection.		
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